Phillip F. Pierce

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

R. Redfield, C. Tacket, D. Birx, 2000, The Journal of infectious diseases.